Shares of Prothena Corp. (NASDAQ:PRTA) were up 4.3% during mid-day trading on Thursday . The stock traded as high as $45.68 and last traded at $45.31, with a volume of 334,703 shares trading hands. The stock had previously closed at $43.46.

A number of analysts have recently weighed in on PRTA shares. Zacks Investment Research upgraded Prothena Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, April 7th. Royal Bank Of Canada reiterated a “buy” rating on shares of Prothena Corp. in a research report on Wednesday, June 22nd. Barclays PLC started coverage on Prothena Corp. in a research report on Friday, May 13th. They set an “overweight” rating and a $60.00 price target on the stock. Credit Suisse Group AG reiterated a “buy” rating on shares of Prothena Corp. in a research report on Tuesday. Finally, Wedbush reiterated an “outperform” rating and set a $77.00 price target on shares of Prothena Corp. in a research report on Tuesday, July 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $74.60.

The stock has a 50-day moving average price of $43.32 and a 200 day moving average price of $42.28. The firm’s market capitalization is $1.57 billion.

Prothena Corp. (NASDAQ:PRTA) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.04. On average, equities research analysts anticipate that Prothena Corp. will post ($3.72) earnings per share for the current fiscal year.

In related news, Director Dennis J. Selkoe sold 5,000 shares of Prothena Corp. stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $45.00, for a total transaction of $225,000.00. Following the sale, the director now directly owns 3,025 shares of the company’s stock, valued at $136,125. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of large investors have recently added to or reduced their stakes in PRTA. State Board of Administration of Florida Retirement System increased its stake in Prothena Corp. by 4.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 17,358 shares of the company’s stock worth $1,182,000 after buying an additional 803 shares during the period. Morgan Stanley increased its stake in Prothena Corp. by 10.8% in the fourth quarter. Morgan Stanley now owns 18,747 shares of the company’s stock worth $1,278,000 after buying an additional 1,830 shares during the period. ProShare Advisors LLC increased its stake in Prothena Corp. by 11.1% in the fourth quarter. ProShare Advisors LLC now owns 29,906 shares of the company’s stock worth $2,037,000 after buying an additional 2,990 shares during the period. Rhumbline Advisers increased its stake in Prothena Corp. by 7.5% in the fourth quarter. Rhumbline Advisers now owns 30,805 shares of the company’s stock worth $2,098,000 after buying an additional 2,140 shares during the period. Finally, New York State Common Retirement Fund increased its stake in Prothena Corp. by 4.0% in the fourth quarter. New York State Common Retirement Fund now owns 31,000 shares of the company’s stock worth $2,111,000 after buying an additional 1,200 shares during the period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.